Table 1

- Descriptive characteristics of the study participants overall and by initial risk status (N=230).

VariablesTotalInitial riskP-values
Low (n=104)Intermediate (n=71)High (n=55)
Age (years), mean±SD41.33±14.5341.14±12.1938.44±15.4045.40±16.640.03
Age
≤55 years191 (83.0)90 (86.5)61 (85.9)40 (72.7)0.06
>55 years39 (17.0)14 (13.5)10 (14.1)15 (27.3)
Gender
Male60 (26.1)13 (12.5)25 (35.2)22 (40.0)<0.0001
Female170 (73.9)91 (87.5)46 (64.8)33 (60.0)
Pathology
Papillary213 (92.6)99 (95.2)65 (91.5)49 (89.1)0.29
Follicular or oncocytic17 (7.4)5 (4.8)6 (8.5)6 (10.9)
N
N0 or NX156 (67.8)100 (96.2)28 (39.4)28 (50.9)<0.0001
N174 (32.2)4 (3.8)43 (60.6)27 (49.1)
M
M0210 (91.3)104 (100)71 (100)35 (63.6)<0.0001
M120 (8.7)0 (0.0)0 (0.0)20 (36.4)
Vascular invasion54 (26.5)0 (0.0)31 (50.8)23 (48.9)<0.0001
Margin involvement41 (20.9)6 (6.6)17 (27.9)18 (40.9)<0.0001
Extrathyroidal extension34 (15.7)0 (0.0)13 (19.04)21 (42.0)<0.0001
Variant
Non papillary15 (8.1)5 (5.8)4 (7.3)6 (13.6)0.001
PTC-low risk variants157 (84.9)81 (94.2)46 (83.6)30 (68.2)
PTC-high risk variants13 (7.0)0 (0.0)5 (9.1)8 (18.2)
Multifocality106 (49.5)40 (40.4)37 (55.2)29 (60.4)0.04
Size of the largest focus (cm), median (Q1, Q3)2.3 (1.0, 4.0)1.5 (0.8, 3.0)3.0 (2.0, 4.0)3.5 (1.5, 5.0)<0.0001
Size of the largest focus
≤4 cm164 (81.2)83 (86.5)50 (82.0)31 (68.9)0.04
>4 cm38 (18.8)13 (13.5)11 (18.0)14 (31.1)
Size of the largest focus
≤2.3 cm104 (51.5)65 (67.7)21 (34.4)18 (40.0)<0.0001
>2.3 cm98 (48.5)31 (32.3)40 (65.6)27 (60.0)
Stage at diagnosis
1202 (87.8)104 (100.0)65 (91.5)33 (60.0)<0.0001
218 (7.8)0 (0.0)6 (8.5)12 (21.8)
35 (2.2)0 (0.0)0 (0.0)5 (9.1)
4b5 (2.2)0 (0.0)0 (0.0)5 (9.1)
Type of surgery
Lobectomy/hemithyroidectomy11 (4.8)8 (7.7)1 (1.4)2 (3.6)0.14
Total or subtotal thyroidectomy219 (95.2)96 (92.3)70 (98.6)53 (96.4)
Given at least one RAI, dose ≥30 mCi183 (79.6)67 (64.4)67 (94.4)49 (89.1)<0.0001

Values are presented as numbers and precentages (%), mean ± standard deviation (SD), or median (first quartile [Q1], third quartile [Q3]).

PTC: papillary thyroid cancer, RAI: radioactive iodine